Remove Leads Remove Pharma Remove Prescription Remove Transportation
article thumbnail

Leading retail pharmacies in pharma

Pharmaceutical Technology

Increasing diagnosis of chronic diseases is expected to lead to fast growth in retail pharmacies. Prescription refill and generic drug programmes. Prescription collection lockers. The post Leading retail pharmacies in pharma appeared first on Pharmaceutical Technology. Speciality care. Compounding services.

Retail 59
article thumbnail

Ipsen concludes purchase of Albireo Pharma

Pharmaceutical Technology

French biopharmaceutical firm Ipsen has concluded the purchase of US-based Albireo Pharma , expanding its rare disease portfolio. Albireo’s pipeline includes its lead asset, Bylvay (odevixibat), a potent, once-a-day, oral, non-systemic, ileal bile acid transport inhibitor (IBATi).

Pharma 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Leading pharmaceutical wholesalers

Pharmaceutical Technology

Pharmaceutical Technology has listed some of the leading wholesalers of pharmaceutical products based on its intel, insights, and decades of experience in the sector. The post Leading pharmaceutical wholesalers appeared first on Pharmaceutical Technology. GDP and GMP advisory. Temperature control facilities and supply solutions.

Leads 52
article thumbnail

Addressing the Polypharmacy Problem

PM360

If one of those conditions is type 2 diabetes, that person may be taking seven prescription medications, 1 managing two or more additional chronic conditions, 2 and paying $13,000 per year on healthcare. senior adults (aged 65+) 7 taking five or more prescription medications. 3 They are also 2.6 In the U.S., 5 This links to 22% of U.S.

article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

Pharma will be focusing more on relevant research, support, and a better mix of non-promotional and promotional interaction. Given the funding environment for innovative medicines that is faced by all pharma, large or small, once assets are approved, however, this 2023 reset seems a necessary response.

article thumbnail

Two Key Questions About Adherence/Compliance in 2023

PM360

Jay Patel From our experience in patient research across many different treatments, we’ve defined several key insights on what may lead to nonadherence: Complex medication routines and patients feeling overwhelmed with their regimen. What if the industry were to incentivize persistence over new prescriptions?

article thumbnail

Access solutions: the missing link that prevents biopharma innovation from reaching patients

pharmaphorum

Uniquely positioned, traditional patient access hubs promise to simplify the process of getting patients started on therapy and offer to provide HCPs with much-needed assistance in navigating payer requirements leading up to therapy starts. Technology is upending every aspect of our lives, from retail to transportation.